Cipla gains on launching Niveoli HFA inhaler for adults

Cipla is currently trading at Rs. 546.90, up by 2.55 points or 0.47% from its previous closing of Rs. 544.35 on the BSE. The scrip opened at Rs. 550.00 and has touched a high and low of Rs. 550.00 and Rs. 546.05 respectively. The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 678.00 on 19-Sep-2018 and a 52 week low of Rs. 483.75 on 29-Jan-2019.

Last one week high and low of the scrip stood at Rs. 554.40 and Rs. 523.20 respectively. The current market cap of the company is Rs. 43858.35 crore. The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 39.60% and 23.69% respectively.

Cipla has launched Niveoli, India’s first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targeting drug delivery to the small airways. Niveoli is a proprietary Cipla inhaler, and the latest offering from Cipla in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD).

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

The post Cipla gains on launching Niveoli HFA inhaler for adults appeared first on Udaipur News | Udaipur Latest News | udaipur local news.

Leave a Reply

Your email address will not be published. Required fields are marked *